Oralject Sedazine - A.C.P Oral Tranquiliser for Horses and Cattle

Virbac (Australia) Pty Limited

Chemwatch Hazard Alert Code: **2**

Chemwatch: **3725455**
Version No: **5.1.1.1**
Safety Data Sheet according to WHS and ADG requirements

Issue Date: **10/04/2017**
Print Date: **10/06/2017**
L.GHS.AUS.EN

SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

Product Identifier

Product name	Oralject Sedazine - A.C.P Oral Tranquiliser for Horses and Cattle
Synonyms	APVMA No: 38769
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	An aid in quitening excitable, nervous, unruly or hard to handle horses and cattle.

Details of the supplier of the safety data sheet

Registered company name	**Virbac (Australia) Pty Limited**
Address	361 Horsley Road Milperra NSW 2214 Australia
Telephone	1800 242 100
Fax	+61 2 9772 9773
Website	www.virbac.com.au
Email	au_customerservice@virbac.com.au

Emergency telephone number

Association / Organisation	**Poisons Information Centre**
Emergency telephone numbers	13 11 26
Other emergency telephone numbers	Not Available

SECTION 2 HAZARDS IDENTIFICATION

Classification of the substance or mixture

Poisons Schedule	S4
Classification	Not Applicable

Label elements

Hazard pictogram(s)	Not Applicable
SIGNAL WORD	**NOT APPLICABLE**

Hazard statement(s)

Not Applicable

Precautionary statement(s) Prevention

Not Applicable

Precautionary statement(s) Response

Not Applicable

Precautionary statement(s) Storage

Not Applicable

Precautionary statement(s) Disposal

Not Applicable

SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

Substances

See section below for composition of Mixtures

Mixtures

Continued...

CAS No	%[weight]	Name
8012-95-1.	>60	paraffin oils
7631-86-9	10-20	silica amorphous
3598-37-6	1.2	acepromazine maleate
		(12g/L)
Not Available	10-30	Ingredients determined not to be hazardous

SECTION 4 FIRST AID MEASURES

Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: ▸ Wash out immediately with fresh running water. ▸ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. ▸ Seek medical attention without delay; if pain persists or recurs seek medical attention. ▸ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: ▸ Immediately remove all contaminated clothing, including footwear. ▸ Flush skin and hair with running water (and soap if available). ▸ Seek medical attention in event of irritation.
Inhalation	▸ If fumes, aerosols or combustion products are inhaled remove from contaminated area. ▸ Other measures are usually unnecessary.
Ingestion	▸ If swallowed do **NOT** induce vomiting. ▸ If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. ▸ Observe the patient carefully. ▸ Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. ▸ Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. ▸ Seek medical advice.

Indication of any immediate medical attention and special treatment needed

The management of NMS (Neuroleptic Malignant syndrome) should include:
- immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy;
- intensive symptomatic treatment and medical monitoring and
- treatment of any concomitant serious medical problems for which specific treatments are available.
- There is no general agreement about specific pharmacological regimes for NMS.
- Heavy and persistent skin contamination over many years may lead to dysplastic changes. Pre-existing skin disorders may be aggravated by exposure to this product.
- In general, emesis induction is unnecessary with high viscosity, low volatility products, i.e. most oils and greases.
- High pressure accidental injection through the skin should be assessed for possible incision, irrigation and/or debridement.

NOTE: Injuries may not seem serious at first, but within a few hours tissue may become swollen, discoloured and extremely painful with extensive subcutaneous necrosis. Product may be forced through considerable distances along tissue planes.

Following recent ingestion of an overdose of phenothiazine sedatives, the stomach should be emptied by gastric lavage, and aspiration. Management should include intensive symptomatic, and supportive therapy. In particular attention should be paid to the maintenance of respiratory and renal function and to the maintenance of electrolyte balance. Phenothiazine-induced hypotension should **NOT** be managed with adrenalin or other sympathomimetics with beta-adrenergic agonist properties since the alpha-blocking effects of phenothiazines impair vasoconstriction and these agents may exacerbate hypotension. MARTINDALE: The Extra Pharmacopoeia, 29th Edition.

SECTION 5 FIREFIGHTING MEASURES

Extinguishing media

- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.
- Water spray or fog - Large fires only.

Special hazards arising from the substrate or mixture

Fire Incompatibility	▸ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

Advice for firefighters

Fire Fighting	▸ Alert Fire Brigade and tell them location and nature of hazard. ▸ Wear breathing apparatus plus protective gloves. ▸ Prevent, by any means available, spillage from entering drains or water courses. ▸ Use water delivered as a fine spray to control fire and cool adjacent area. ▸ **DO NOT** approach containers suspected to be hot. ▸ Cool fire exposed containers with water spray from a protected location. ▸ If safe to do so, remove containers from path of fire. ▸ Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	▸ Combustible. ▸ Slight fire hazard when exposed to heat or flame. ▸ Heating may cause expansion or decomposition leading to violent rupture of containers. ▸ On combustion, may emit toxic fumes of carbon monoxide (CO). ▸ May emit acrid smoke. ▸ Mists containing combustible materials may be explosive. Combustion products include: , carbon monoxide (CO) , carbon dioxide (CO2)

Continued...

	, silicon dioxide (SiO2) , other pyrolysis products typical of burning organic material. May emit poisonous fumes. May emit corrosive fumes. **CARE**: Water in contact with hot liquid may cause foaming and a steam explosion with wide scattering of hot oil and possible severe burns. Foaming may cause overflow of containers and may result in possible fire.
HAZCHEM	Not Applicable

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	Slippery when spilt. ▸ Clean up all spills immediately. ▸ Avoid contact with skin and eyes. ▸ Wear impervious gloves and safety goggles. ▸ Trowel up/scrape up. ▸ Place spilled material in clean, dry, sealed container. ▸ Flush spill area with water.
Major Spills	Slippery when spilt. ▸ Clear area of personnel and move upwind. ▸ Alert Fire Brigade and tell them location and nature of hazard. ▸ Wear breathing apparatus plus protective gloves. ▸ Prevent, by any means available, spillage from entering drains or water course. ▸ Stop leak if safe to do so. ▸ Contain spill with sand, earth or vermiculite. ▸ Collect recoverable product into labelled containers for recycling. ▸ Neutralise/decontaminate residue (see Section 13 for specific agent). ▸ Collect solid residues and seal in labelled drums for disposal. ▸ Wash area and prevent runoff into drains. ▸ After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. ▸ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 HANDLING AND STORAGE

Precautions for safe handling

Safe handling	▸ Avoid all personal contact, including inhalation. ▸ Wear protective clothing when risk of exposure occurs. ▸ Use in a well-ventilated area. ▸ Prevent concentration in hollows and sumps. ▸ **DO NOT** enter confined spaces until atmosphere has been checked. ▸ **DO NOT** allow material to contact humans, exposed food or food utensils. ▸ Avoid contact with incompatible materials. ▸ When handling, **DO NOT** eat, drink or smoke. ▸ Keep containers securely sealed when not in use. ▸ Avoid physical damage to containers. ▸ Always wash hands with soap and water after handling. ▸ Work clothes should be laundered separately. Launder contaminated clothing before re-use. ▸ Use good occupational work practice. ▸ Observe manufacturer's storage and handling recommendations contained within this SDS. ▸ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Other information	▸ Store in original containers. ▸ Keep containers securely sealed. ▸ No smoking, naked lights or ignition sources. ▸ Store in a cool, dry, well-ventilated area. ▸ Store away from incompatible materials and foodstuff containers. ▸ Protect containers against physical damage and check regularly for leaks. ▸ Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container	▸ Metal can or drum ▸ Packaging as recommended by manufacturer. ▸ Check all containers are clearly labelled and free from leaks.
Storage incompatibility	▸ Avoid reaction with oxidising agents

SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Control parameters

OCCUPATIONAL EXPOSURE LIMITS (OEL)

Continued...

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	silica amorphous	Fumed silica (respirable dust)	2 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	silica amorphous	Fumed silica (respirable dust)	2 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	silica amorphous	Diatomaceous earth (uncalcined)	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	silica amorphous	Diatomaceous earth (uncalcined)	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	silica amorphous	Silica, fused	Not Available	Not Available	Not Available	Not Available
Australia Exposure Standards	silica amorphous	Precipitated silica	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	silica amorphous	Precipitated silica	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	silica amorphous	Silica gel	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	silica amorphous	Silica gel	10 mg/m3	Not Available	Not Available	Not Available

EMERGENCY LIMITS

Ingredient	Material name	TEEL-1	TEEL-2	TEEL-3
silica amorphous	Silica gel, amorphous synthetic	18 mg/m3	200 mg/m3	1,200 mg/m3
silica amorphous	Silica, amorphous fumed	18 mg/m3	100 mg/m3	630 mg/m3
silica amorphous	Siloxanes and silicones, dimethyl, reaction products with silica; (Hydrophobic silicon dioxide, amorphous)	120 mg/m3	1,300 mg/m3	7,900 mg/m3
silica amorphous	Silica, amorphous fume	45 mg/m3	500 mg/m3	3,000 mg/m3
silica amorphous	Silica amorphous hydrated	18 mg/m3	220 mg/m3	1,300 mg/m3

Ingredient	Original IDLH	Revised IDLH
paraffin oils	2,500 mg/m3	Not Available
silica amorphous	3,000 mg/m3	Not Available
acepromazine maleate	Not Available	Not Available
Ingredients determined not to be hazardous	Not Available	Not Available

MATERIAL DATA

Exposure controls

Appropriate engineering controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.
The basic types of engineering controls are:
Process controls which involve changing the way a job activity or process is done to reduce the risk.
Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.
Employers may need to use multiple types of controls to prevent employee overexposure.

Local exhaust ventilation usually required. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection.
Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection.
An approved self contained breathing apparatus (SCBA) may be required in some situations.
Provide adequate ventilation in warehouse or closed storage area. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

Continued...

Personal protection	
Eye and face protection	▸ Safety glasses with side shields. ▸ Chemical goggles. ▸ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]
Skin protection	See Hand protection below
Hands/feet protection	▸ Wear chemical protective gloves, e.g. PVC. ▸ Wear safety footwear or safety gumboots, e.g. Rubber **NOTE:** ▸ The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact. ▸ Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.
Body protection	See Other protection below
Other protection	▸ Overalls. ▸ P.V.C. apron. ▸ Barrier cream. ▸ Skin cleansing cream. ▸ Eye wash unit.
Thermal hazards	Not Available

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:
"Forsberg Clothing Performance Index".
The effect(s) of the following substance(s) are taken into account in the ***computer-generated*** selection:
Oralject Sedazine - A.C.P Oral Tranquiliser for Horses and Cattle

Material	CPI
BUTYL	C
NAT+NEOPR+NITRILE	C
NATURAL RUBBER	C
NATURAL+NEOPRENE	C
NEOPRENE	C
NEOPRENE/NATURAL	C
NITRILE	C
NITRILE+PVC	C
PE	C
PE/EVAL/PE	C
PVA	C
PVC	C
SARANEX-23	C
SARANEX-23 2-PLY	C
TEFLON	C
VITON	C
VITON/CHLOROBUTYL	C

* CPI - Chemwatch Performance Index
A: Best Selection
B: Satisfactory; may degrade after 4 hours continuous immersion
C: Poor to Dangerous Choice for other than short term immersion
NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -
* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required.
Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	A-AUS P2	-	A-PAPR-AUS / Class 1 P2
up to 50 x ES	-	A-AUS / Class 1 P2	-
up to 100 x ES	-	A-2 P2	A-PAPR-2 P2 ^

^ - Full-face
A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content. The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Appearance	Bright yellow smooth paste with bland taste - residual bitterness.

Physical state	Non Slump Paste	**Relative density (Water = 1)**	Not Available

Continued...

Odour	Not Available	**Partition coefficient n-octanol / water**	Not Available
Odour threshold	Not Available	**Auto-ignition temperature (°C)**	Not Available
pH (as supplied)	Not Available	**Decomposition temperature**	Not Available
Melting point / freezing point (°C)	Not Available	**Viscosity (cSt)**	Not Available
Initial boiling point and boiling range (°C)	Not Available	**Molecular weight (g/mol)**	Not Applicable
Flash point (°C)	Not Available	**Taste**	Not Available
Evaporation rate	Not Available	**Explosive properties**	Not Available
Flammability	Not Available	**Oxidising properties**	Not Available
Upper Explosive Limit (%)	Not Available	**Surface Tension (dyn/cm or mN/m)**	Not Available
Lower Explosive Limit (%)	Not Available	**Volatile Component (%vol)**	Not Available
Vapour pressure (kPa)	Not Available	**Gas group**	Not Available
Solubility in water (g/L)	Not Available	**pH as a solution (1%)**	Not Available
Vapour density (Air = 1)	Not Available	**VOC g/L**	Not Available

SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7
Chemical stability	▸ Unstable in the presence of incompatible materials. ▸ Product is considered stable. ▸ Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 TOXICOLOGICAL INFORMATION

Information on toxicological effects

Inhaled	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting. Inhalation of oil droplets/ aerosols may cause discomfort and may produce chemical pneumonitis.
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual. Antipsychotics (also known as neuroleptics) are a group of psychoactive drugs commonly but not exclusively used to treat psychosis, which is typified by schizophrenia. Both first generation drugs (typical antipsychotics) and second generation drugs (atypical antipsychotics) tend to block receptors in the brain's dopamine pathways, but antipsychotic drugs encompass a wide range of receptor targets. A number of side effects have been observed in relation to specific medications, including weight gain, agranulocytosis (a potentially dangerous reduction in the number of white blood cells in the body), tardive dyskinesia (involving involuntary, repetitive movements), tardive akathisia (characterised by unpleasant sensations of "inner" restlessness that manifests itself with an inability to sit still or remain motionless), tardive psychoses and tardive dysphrenia (worsening of psychiatric symptoms) Detrimental effects on short term memory, which affect the way one figures and calculates (although this also may be purely subjective), may also be observed on high enough dosages. All antipsychotic drugs tend to block D2 receptors in the dopamine pathways of the brain. This means that dopamine released in these pathways has less effect. Excess release of dopamine in the mesolimbic pathway has been linked to psychotic experiences. It is the blockade of dopamine receptors in this pathway that is thought to control psychotic experiences. Antipsychotic agents do not induce psychological addiction. Compared to the typical antipsychotics, the atypicals are less likely to cause extrapyramidal motor control disabilities in patients, which include unsteady Parkinson's disease-type movements, body rigidity and involuntary tremours. These abnormal body movements can become permanent even after medication is stopped A dopamine antagonist is a drug which blocks dopamine receptors (dopaminergics) by receptor antagonism. They are used, typically as antipsychotics, antiemetics and antidepressants. As peripheral and central dopaminergic receptors are similar, the specificity of action of an antagonist on peripheral or central receptors depends primarily on its pharmacokinetic features. If the drug does not cross the blood-brain barrier to a substantial degree, the peripheral effects will prevail (dopamine antagonists of this type are known as "prokinetic" agents); the opposite is true in the case of good penetration in the brain (the antipsychotics or neuroleptics). The central effects of antipsychotics prevail over their peripheral effects which, nevertheless, remain present. Psychoses, schizophrenia in particular, are very complex diseases involving negative symptoms (poverty of speech and expression, indifference, carelessness etc.) and productive symptoms (hallucinations, delusion, unsuited behavior, , aggressiveness). Antipsychotics, improve most of these symptoms, (especially the productive ones). In animal experiments, antipsychotics agents elicit: ▸ sedation, reduced motility ▸ in high doses, catalepsy, i.e. maintenance of unusual positions given to animals by the experimenter ▸ inhibition of conditioned reflexes with maintenance of primary reflexes ▸ inhibition of agitation, stereotypes, and vomiting induced by apomorphine or amphetamine. In human beings, the effects of antipsychotics are different in healthy subjects compared to patients with psychosis: In healthy subjects they elicit ▸ drowsiness, indifference, and several adverse effects of the same type as those which are described further. In psychotic patients, they have three principal effects: ▸ sedation which results in drowsiness, diminution of vigilance, agitation and excitement ▸ antideliriant and anti-hallucinogenic effects: decrease of delusion and hallucinations ▸ anti-autistic effect: patients become more communicative and have a better contact with reality

Continued...

Antipsychotics have many adverse effects including.
- Sedation, drowsiness.
- Acute dyskinesia which occurs in first hours or first days after the initiation of the treatment by a neuroleptic. Acute dyskinesia is characterised by intermittent muscular spasms, affecting especially face and neck: torticollis, trismus, tongue protrusion, oculogyric attack, opistothonos. These symptoms, linked to inhibition of D2 dopaminergic receptors of the striatum, are distressing but may be controlled by anticholinergic antiparkinsonian drugs such as trihexyphenidyl The frequency of acute dyskinesias is lower with atypical neuroleptics like clozapine, olanzapine, risperidone that with conventional neuroleptics.
- Tardive dyskinesia, or lingual-facial-buccal dyskinesia, which occurs after a long treatment with high doses of antipsychotics. Sufferers may show repetitive, involuntary, purposeless movements often of the lips, face, legs, or torso. It is believed that there is a greater risk of developing tardive dyskinesia with the older, typical antipsychotic drugs, although the newer antipsychotics are now also known to cause this disorder. The development of this syndrome appears to be related to the duration of treatment and the total cumulative dose of antipsychotic drugs administered; the syndrome can, however, develop after relatively brief treatment periods at low doses These abnormal movements persist a long time after the discontinuation of neuroleptic agents, discontinuation which can worsen them. They are not improved by anticholinergic drugs such as trihexyphenidyl.
- Pseudo-parkinsonism with akinesia (slowness of movements), rest and postural tremor, rigidity, hypertonicity. The incidence of these effects is less frequent with atypical antipsychotics.
- Akathisia or impossibility of remaining motionless.
- Rare but severe hyperthermia accompanied by muscular rigidity, called neuroleptic malignant syndrome whose mechanisms are complex .
- Decrease of seizure threshold, for example with clozapine.
- Confusional syndrome: the antimuscarinic effect of most of antipsychotics contributes to appearance of confusional states.
- Passivity and perhaps a certain depressive state.

Digestive
- Mouth dryness
- Hypersalivation, with clozapine for example
- Constipation,often linked to antimuscarinic effects.

Cardiovascular
- Postural hypotension
- Electrocardiographic disorders. A lengthening of QT space was observed during the use of neuroleptics such as droperidol which now is not available in many countries and sultopride by injectable route in the treatment of agitation
- possible implication of neuroleptics in sudden deaths has been evoked.

Endocrine
- Hyperprolactinaemia at the origin of galactorrhea, gynaecomastia, amenorrhea, decreased libido, erection and ejaculation disorders
- weight gain, in particular with atypical neuroleptics such as olanzapine.

Neuroleptics such as clozapine and olanzapine have been suspected to increase the risk of diabetes.

Allergic reactions
- Photosensitisation
- Blood disorders: thrombocytopenia, agranulocytosis particularly with clozapine.

Teratogenesis: The old neuroleptic agents such as chlorpromazine are not teratogenic.

- Antipsychotics, particularly atypicals, appear to cause diabetes mellitus and fatal diabetic ketoacidosis, especially (in US studies) in African Americans.
- Antipsychotics may cause pancreatitis
- The atypical antipsychotics (especially olanzapine) seem to cause weight gain more commonly than the typical antipsychotics. The well-documented metabolic side effects associated with weight gain include diabetes, which can be life-threatening.
- Clozapine also has a risk of inducing agranulocytosis, a potentially dangerous reduction in the number of white blood cells in the body.
- A potentially serious side effect of many antipsychotics is that they tend to lower an individual's seizure threshold. Another antipsychotic side effect is deterioration of teeth due to a lack of saliva.
- Another serious and potentially fatal side effect is sometimes referred to as Neuroleptic Malignant Syndrome, in which the drugs appear to cause the temperature regulation centers to fail, resulting in a medical emergency, as the patient's temperature suddenly increases to dangerous levels. Other signs include muscle rigidity altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria, rhabdomyolysis, and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated.
- Other clinical manifestations include hyperpyrexia, muscle rigidity, altered mental state, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.
- Other side-effects of drug therapy may include a disruption to the body's ability to reduce body core temperature and dysphagia (oesophageal dysmotility and aspiration - aspiration pneumonia is a common cause of morbidity or mortality in elderly patients especially those with advanced Alzheimer's dementia).

A potentially fatal symptom complex, sometimes referred to as Neuroleptic Malignant Syndrome (NMS), has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias).
Dopamine has an emetic effect and inhibits digestive motility; its antagonists have antiemetic and digestive motility stimulant effects. Dopaminergic receptors in the chemoreceptor trigger zone responsible for vomiting are accessible to dopaminergic antagonists which do not cross the blood-brain barrier. Drugs stimulating gastrointestinal motility are called prokinetic agents and are used specially in treating gastroesophageal reflux.
Many side effects produced by the tricyclic antidepressants are caused by their anticholinergic actions. These include dry mouth, sour or metallic taste, constipation (leading occasionally to paralytic ileum), urinary retention, blurred vision and changes in accommodation, palpitations and tachycardia. Gastrointestinal disturbances (including nausea and vomiting), Drowsiness, tremor, orthostatic hypotension (or occasional hypertension), dizziness, sweating, weakness and fatigue, ataxia, epileptiform seizures, occasional extrapyramidal symptoms (including speech difficulties) may also occur. Allergic skin reactions and photosensitisation have been reported. Rarely, jaundice and blood disorders (including eosinophilia, bone-marrow depression, thrombocytopenia and agranulocytosis) have also been reported. Myocardium effects may produce conduction defects and cardiac arrhythmias. Endocrine effects may produce changes in libido, impotence, enlarged breasts and gynaecomastia and galactorrhoea. Changes in blood sugar levels and reduced levels of antidiuretic hormone may also occur. Overdose may produce excitement and restlessness with marked anticholinergic effects (dry mouth, dilated pupils, tachycardia, urinary retention and absence of bowel sounds). More severe poisonings may produce convulsions and myoclonus, hypotension, respiratory and cardiac depression. Life-threatening arrhythmias may recur some days after apparent recovery.
Tricyclic antidepressants may be monoamine oxidase inhibitors (MAOIs). Monoamine oxidase inhibitors produce postural hypotension, dizziness, drowsiness, weakness and fatigue, dryness of the mouth, constipation and other gastrointestinal disturbances (including nausea and vomiting) and oedema. Other symptoms may include agitation and tremors, insomnia and restless sleep, blurred vision, difficulty in urinating, convulsions, skin rashes, leucopenia, sexual disturbances and weight gain with inappropriate appetite. Psychotic episodes may be characterised by hypomanic behavior, confusion and hallucinations. Jaundice has been reported and infrequently this may lead to fatal progressive hepatocellular necrosis.
Patients of any age with Major Depressive Disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behaviour (suicidality), whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Patients should be closely monitored, especially at the beginning of therapy or when the dose is changed, until such improvement occurs.
There has been a long-standing concern that some antidepressants may have a role in the emergence of suicidality in some patients. The possible risk of increased suicidality in patients applies to all classes of antidepressant medicines, as available data are not adequate to exclude this risk for any antidepressant. Therefore, consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or whose emergent suicidality is severe, abrupt in onset, or was not part of the patient's presenting symptoms.
Generally, when stopping an antidepressant, doses should be tapered rather than stopped abruptly.
The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania and mania, have been reported in adult and paediatric patients being treated with antidepressants for major depressive disorder as well as for

Continued...

	other indications, both psychiatric and non-psychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients for whom such symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Because of the possibility of co-morbidity between major depressive disorder and other psychiatric and non-psychiatric disorders, the same precautions observed when treating patients with major depressive disorder should be observed when treating patients with other psychiatric and non-psychiatric disorders. **Mania and Bipolar Disorder:** A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with any antidepressant alone may increase the likelihood of a mixed-manic episode in patients at risk for bipolar disorder. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder.
Skin Contact	Limited evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. Open cuts, abraded or irritated skin should not be exposed to this material The material may accentuate any pre-existing dermatitis condition Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.
Eye	Limited evidence exists, or practical experience suggests, that the material may cause eye irritation in a substantial number of individuals and/or is expected to produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.
Chronic	Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems. There exists limited evidence that shows that skin contact with the material is capable either of inducing a sensitisation reaction in a significant number of individuals, and/or of producing positive response in experimental animals. There is some evidence that human exposure to the material may result in developmental toxicity. This evidence is based on animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects. An increase in the incidence of mammary adenocarcinomas is a common finding for D2 antagonists which increase prolactin secretion when administered to rats. An increase in the incidence of pancreatic islet cell tumours has been observed for some other D2 antagonists. The physiological differences between rats and humans with regard to prolactin make the clinical significance of these findings unclear. . In humans, chorionic gonadotropin, not prolactin, is essential for implantation Antipsychotic drugs have been shown to chronically elevate prolactin levels in rodents. Increases in mammary neoplasms have been found in rodents after chronic administration of antipsychotic drugs and are considered to be prolactin-mediated. Increased prolactin levels in serum are a secondary consequence of chronic dopamine antagonism of pituitary lactotrophs. The relevance of the increased incidence of prolactin-mediated mammary gland tumours in rats, to human risk, is unknown. Reproductive and developmental toxicity may also result from exposure to dopamine antagonists; these may result from elevation of serum prolactin. Effects may include prolonged oestrus, pre-implantation loss and alterations to the length of the gestational cycle. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynaecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients On the basis, primarily, of animal experiments, concern has been expressed that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment. The synthetic, amorphous silicas are believed to represent a very greatly reduced silicosis hazard compared to crystalline silicas and are considered to be nuisance dusts. When heated to high temperature and a long time, amorphous silica can produce crystalline silica on cooling. Inhalation of dusts containing crystalline silicas may lead to silicosis, a disabling pulmonary fibrosis that may take years to develop. Discrepancies between various studies showing that fibrosis associated with chronic exposure to amorphous silica and those that do not may be explained by assuming that diatomaceous earth (a non-synthetic silica commonly used in industry) is either weakly fibrogenic or nonfibrogenic and that fibrosis is due to contamination by crystalline silica content Mildly-treated solvent refined oils, both naphthenic and paraffinic, induce skin tumours after repeated skin applications in mice. Severe solvent-refining, by contrast, does not induce such tumours. Oral administration of phenothiazines with an aliphatic side chain, during the first three months of pregnancy, has been associated with malformations amongst offspring. Principal route of exposure is by skin contact; lesser exposures include inhalation of fumes from hot oils, oil mists or droplets. Prolonged contact with mineral oils carries with it the risk of skin conditions such as oil folliculitis, eczematous dermatitis, pigmentation of the face (melanosis) and warts on the sole of the foot (plantar warts). With highly refined mineral oils no appreciable systemic effects appear to result through skin absorption. Exposure to oil mists frequently elicits respiratory conditions, such as asthma; the provoking agent is probably an additive. High oil mist concentrations may produce lipoid pneumonia although clinical evidence is equivocal. In animals exposed to concentrations of 100 mg/m3 oil mist, for periods of 12 to 26 months, the activity of lung and serum alkaline phosphatase enzyme was raised; 5 mg/m3 oil mist did not produce this response. These enzyme changes are sensitive early indicators of lung damage. Workers exposed to vapours of mineral oil and kerosene for 5 to 35 years showed an increased prevalence of slight basal lung fibrosis.

Oralject Sedazine - A.C.P Oral Tranquiliser for Horses and Cattle	**TOXICITY**	**IRRITATION**
	Not Available	Not Available

paraffin oils	**TOXICITY**	**IRRITATION**
	Inhalation (rat) LC50: 2059.647258 mg/l/4H[2]	Eye (rabbit): 500 mg moderate
		Skin (rabbit): 100 mg/24h mild

silica amorphous	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: >5000 mg/kg[2]	Eye (rabbit): non-irritating *
	Inhalation (rat) LC50: >0.139 mg/l/14h**[Grace][2]	Skin (rabbit): non-irritating *
	Oral (rat) LD50: 3160 mg/kg[2]	

Continued...

acepromazine maleate	**TOXICITY**	**IRRITATION**
	Oral (rat) LD50: 400 mg/kg[2]	Not Available

Legend:	*1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances*

PARAFFIN OILS

The materials included in the Lubricating Base Oils category are related from both process and physical-chemical perspectives;
The potential toxicity of a specific distillate base oil is inversely related to the severity or extent of processing the oil has undergone, since:

- The adverse effects of these materials are associated with undesirable components, and
- The levels of the undesirable components are inversely related to the degree of processing;
- Distillate base oils receiving the same degree or extent of processing will have similar toxicities;
- The potential toxicity of *residual base oils* is independent of the degree of processing the oil receives.
- The reproductive and developmental toxicity of the distillate base oils is inversely related to the degree of processing.

Unrefined & mildly refined distillate base oils contain the highest levels of undesirable components, have the largest variation of hydrocarbon molecules and have shown the highest potential carcinogenic and mutagenic activities. Highly and severely refined distillate base oils are produced from unrefined and mildly refined oils by removing or transforming undesirable components. In comparison to unrefined and mildly refined base oils, the highly and severely refined distillate base oils have a smaller range of hydrocarbon molecules and have demonstrated very low mammalian toxicity. Mutagenicity and carcinogenicity testing of residual oils has been negative, supporting the belief that these materials lack biologically active components or the components are largely non-bioavailable due to their molecular size.
Toxicity testing has consistently shown that lubricating base oils have low acute toxicities. Numerous tests have shown that a lubricating base oil's mutagenic and carcinogenic potential correlates with its 3-7 ring polycyclic aromatic compound (PAC) content, and the level of DMSO extractables (e.g. IP346 assay), both characteristics that are directly related to the degree/conditions of processing
Highly and Severely Refined Distillate Base Oils
Acute toxicity: Multiple studies of the acute toxicity of highly & severely refined base oils have been reported. Irrespective of the crude source or the method or extent of processing, the oral LD50s have been observed to be >5 g/kg (bw) and the dermal LD50s have ranged from >2 to >5g/kg (bw). The LC50 for inhalation toxicity ranged from 2.18 mg/l to> 4 mg/l.
When tested for skin and eye irritation, the materials have been reported as "non-irritating" to "moderately irritating"
Testing in guinea pigs for sensitization has been negative
Repeat dose toxicity: . Several studies have been conducted with these oils**. T**he weight of evidence from all available data on highly & severely refined base oils support the presumption that a distillate base oil's toxicity is inversely related to the degree of processing it receives. Adverse effects have been reported with even the most severely refined white oils - these appear to depend on animal species and/ or the peculiarities of the study.

- The granulomatous lesions induced by the oral administration of white oils are essentially foreign body responses. The lesions occur only in rats, of which the Fischer 344 strain is particularly sensitive,
- The testicular effects seen in rabbits after dermal administration of a highly to severely refined base oil were unique to a single study and may have been related to stress induced by skin irritation, and
- The accumulation of foamy macrophages in the alveolar spaces of rats exposed repeatedly via inhalation to high levels of highly to severely refined base oils is not unique to these oils, but would be seen after exposure to many water insoluble materials.

Reproductive and developmental toxicity: A highly refined base oil was used as the vehicle control in a one-generation reproduction study. The study was conducted according to the OECD Test Guideline 421. There was no effect on fertility and mating indices in either males or females. At necropsy, there were no consistent findings and organ weights and histopathology were considered normal by the study's authors.
A single generation study in which a white mineral oil (a food/ drug grade severely refined base oil) was used as a vehicle control is reported. Two separate groups of pregnant rats were administered 5 ml/kg (bw)/day of the base oil via gavage, on days 6 through 19 of gestation. In one of the two base oil dose groups, three malformed foetuses were found among three litters The study authors considered these malformations to be minor and within the normal ranges for the strain of rat.
Genotoxicity:
In vitro (mutagenicity): Several studies have reported the results of testing different base oils for mutagenicity using a modified Ames assay Base oils with no or low concentrations of 3-7 ring PACs had low mutagenicity indices.
In vivo (chromosomal aberrations): A total of seven base stocks were tested in male and female Sprague-Dawley rats using a bone marrow cytogenetics assay. The test materials were administered via gavage at dose levels ranging from 500 to 5000 mg/kg (bw). Dosing occurred for either a single day or for five consecutive days. None of the base oils produced a significant increase in aberrant cells.
Carcinogenicity: Highly & severely refined base oils are not carcinogens, when given either orally or dermally.
Equivocal tumorigen by RTECS criteria

SILICA AMORPHOUS

For silica amorphous:
When experimental animals inhale synthetic amorphous silica (SAS) dust, it dissolves in the lung fluid and is rapidly eliminated. If swallowed, the vast majority of SAS is excreted in the faeces and there is little accumulation in the body. Following absorption across the gut, SAS is eliminated via urine without modification in animals and humans. SAS is not expected to be broken down (metabolised) in mammals.
After ingestion, there is limited accumulation of SAS in body tissues and rapid elimination occurs. Intestinal absorption has not been calculated, but appears to be insignificant in animals and humans. SASs injected subcutaneously are subjected to rapid dissolution and removal. There is no indication of metabolism of SAS in animals or humans based on chemical structure and available data. In contrast to crystalline silica, SAS is soluble in physiological media and the soluble chemical species that are formed are eliminated via the urinary tract without modification.
Both the mammalian and environmental toxicology of SASs are significantly influenced by the physical and chemical properties, particularly those of solubility and particle size. SAS has no acute intrinsic toxicity by inhalation. Adverse effects, including suffocation, that have been reported were caused by the presence of high numbers of respirable particles generated to meet the required test atmosphere. These results are not representative of exposure to commercial SASs and should not be used for human risk assessment. Though repeated exposure of the skin may cause dryness and cracking, SAS is not a skin or eye irritant, and it is not a sensitiser.
Repeated-dose and chronic toxicity studies confirm the absence of toxicity when SAS is swallowed or upon skin contact.
Long-term inhalation of SAS caused some adverse effects in animals (increases in lung inflammation, cell injury and lung collagen content), all of which subsided after exposure.
Numerous repeated-dose, subchronic and chronic inhalation toxicity studies have been conducted with SAS in a number of species, at airborne concentrations ranging from 0.5 mg/m3 to 150 mg/m3. Lowest-observed adverse effect levels (LOAELs) were typically in the range of 1 to 50 mg/m3. When available, the no-observed adverse effect levels (NOAELs) were between 0.5 and 10 mg/m3. The difference in values may be explained by different particle size, and therefore the number of particles administered per unit dose. In general, as particle size decreases so does the NOAEL/LOAEL.
Neither inhalation nor oral administration caused neoplasms (tumours). SAS is not mutagenic in vitro. No genotoxicity was detected in in vivo assays. SAS does not impair development of the foetus. Fertility was not specifically studied, but the reproductive organs in long-term studies were not affected.
In humans, SAS is essentially non-toxic by mouth, skin or eyes, and by inhalation. Epidemiology studies show little evidence of adverse health effects due to SAS. Repeated exposure (without personal protection) may cause mechanical irritation of the eye and drying/cracking of the skin.
There is no evidence of cancer or other long-term respiratory health effects (for example, silicosis) in workers employed in the manufacture of SAS. Respiratory symptoms in SAS workers have been shown to correlate with smoking but not with SAS exposure, while serial pulmonary function values and chest radiographs are not adversely affected by long-term exposure to SAS.
The substance is classified by IARC as Group 3:
NOT classifiable as to its carcinogenicity to humans.
Evidence of carcinogenicity may be inadequate or limited in animal testing.
Reports indicate high/prolonged exposures to amorphous silicas induced lung fibrosis in experimental animals; in some experiments these effects were reversible. [PATTYS]

Continued...

Acute Toxicity	⊘	**Carcinogenicity**	⊘
Skin Irritation/Corrosion	⊘	**Reproductivity**	⊘
Serious Eye Damage/Irritation	⊘	**STOT - Single Exposure**	⊘
Respiratory or Skin sensitisation	⊘	**STOT - Repeated Exposure**	⊘
Mutagenicity	⊘	**Aspiration Hazard**	⊘

Legend: ✗ *– Data available but does not fill the criteria for classification*
✓ *– Data available to make classification*
⊘ *– Data Not Available to make classification*

SECTION 12 ECOLOGICAL INFORMATION

Toxicity

Oralject Sedazine - A.C.P Oral Tranquiliser for Horses and Cattle

ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE
Not Available	Not Available	Not Available	Not Available	Not Available

paraffin oils

ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE
LC50	96	Fish	>100mg/L	4

silica amorphous

ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE
LC50	96	Fish	ca.2000mg/L	1
EC50	48	Crustacea	ca.7600mg/L	1
EC50	72	Algae or other aquatic plants	440mg/L	1
EC10	72	Algae or other aquatic plants	140mg/L	1
NOEC	72	Algae or other aquatic plants	60mg/L	1

acepromazine maleate

ENDPOINT	TEST DURATION (HR)	SPECIES	VALUE	SOURCE
Not Available	Not Available	Not Available	Not Available	Not Available

Legend: *Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data*

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
silica amorphous	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
silica amorphous	LOW (LogKOW = 0.5294)

Mobility in soil

Ingredient	Mobility
silica amorphous	LOW (KOC = 23.74)

SECTION 13 DISPOSAL CONSIDERATIONS

Waste treatment methods

Product / Packaging disposal

- Recycle wherever possible or consult manufacturer for recycling options.
- Consult State Land Waste Authority for disposal.
- Bury or incinerate residue at an approved site.
- Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 TRANSPORT INFORMATION

Labels Required

Marine Pollutant	NO
HAZCHEM	Not Applicable

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Continued...

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

SECTION 15 REGULATORY INFORMATION

Safety, health and environmental regulations / legislation specific for the substance or mixture

PARAFFIN OILS(8012-95-1.) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Exposure Standards
Australia Hazardous Substances Information System - Consolidated Lists
Australia Inventory of Chemical Substances (AICS)
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

SILICA AMORPHOUS(7631-86-9) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Exposure Standards
Australia Hazardous Substances Information System - Consolidated Lists
Australia Inventory of Chemical Substances (AICS)
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

ACEPROMAZINE MALEATE(3598-37-6) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Inventory of Chemical Substances (AICS)

National Inventory	Status
Australia - AICS	Y
Canada - DSL	Y
Canada - NDSL	N (paraffin oils; acepromazine maleate)
China - IECSC	N (acepromazine maleate)
Europe - EINEC / ELINCS / NLP	Y
Japan - ENCS	N (paraffin oils; acepromazine maleate)
Korea - KECI	N (acepromazine maleate)
New Zealand - NZIoC	Y
Philippines - PICCS	N (acepromazine maleate)
USA - TSCA	N (acepromazine maleate)
Legend:	*Y = All ingredients are on the inventory* *N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)*

SECTION 16 OTHER INFORMATION

Other information

Ingredients with multiple cas numbers

Name	CAS No
paraffin oils	8012-95-1., 8043-78-5, 37231-69-9, 37232-05-6, 188832-17-9, 79956-36-8, 172307-10-7, 58615-80-8, 187112-19-2, 219686-29-0, 261380-10-3, 74870-90-9, 97048-20-9, 58391-38-1, 331464-54-1, 99551-14-1, 8039-75-6, 8039-14-3, 8038-04-8, 8033-89-4, 60327-80-2, 39464-77-2, 39290-23-8, 83046-05-3, 51004-58-1, 39296-25-8, 50935-95-0, 122176-99-2, 39464-78-3, 51109-96-7, 39355-35-6, 39355-09-4, 39355-08-3, 106803-31-0, 115251-26-8, 116357-36-9, 50935-85-8, 37232-07-8, 146908-77-2, 37232-06-7, 53028-74-3, 52012-28-9, 52012-27-8, 8015-59-6, 102819-98-7
silica amorphous	7631-86-9, 112945-52-5, 67762-90-7, 68611-44-9, 68909-20-6, 112926-00-8, 61790-53-2, 60676-86-0, 91053-39-3, 69012-64-2, 844491-94-7

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average
PC—STEL: Permissible Concentration-Short Term Exposure Limit
IARC: International Agency for Research on Cancer
ACGIH: American Conference of Governmental Industrial Hygienists
STEL: Short Term Exposure Limit
TEEL: Temporary Emergency Exposure Limit。
IDLH: Immediately Dangerous to Life or Health Concentrations
OSF: Odour Safety Factor
NOAEL :No Observed Adverse Effect Level
LOAEL: Lowest Observed Adverse Effect Level
TLV: Threshold Limit Value
LOD: Limit Of Detection
OTV: Odour Threshold Value
BCF: BioConcentration Factors
BEI: Biological Exposure Index

Continued...

TEL (+61 3) 9572 4700.

end of SDS